Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US
Gains 180 Days Of CGT Exclusivity For Generic Of Ortho Evra Contraceptive Patch
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.
You may also be interested in...
Viatris has reiterated the strength of its biosimilars and complex generics pipeline, highlighting opportunities including biosimilar Eylea, Botox and once-a-month Copaxone.
Amneal says it is taking initiatives to improve its generics margins by improving its manufacturing and supply chain, after its generics segment was sales drop by 11% in the first quarter. Amneal is aiming to deliver six to seven high-value products annually, while the company is also looking to launch three biosimilars in the next couple of years.
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.